KLab manufactures, markets and out-licenses patented Pharmaceutical Formulations, NDDS, niche API’s and chiral intermediates.

KLab’s major sales are from patented products from in-house R&D. Cefi-XL our patented antibiotic combination is the No.1 launched new product in India in last 2 years as per July 2006 IMS report.

KLab has more than 150 patents granted/pending using NDDS,
Nanotechnology, Dendrimers and Chiral Chemistry.

KLab is ranked 57th in the Indian Pharmaceutical Industry as per IMS ORG, & KLab is ranked 26th as per its covered market and is growing above 30% per annum. Within next 3 years, KLab plans to be around number 10th rank in its covered market.

KLab has over 2000 employees. The sales force comprises around 1500 persons who cover 250,000 Doctors, 100,000 Pharmacies and 1500 Stockists in India every month.

KLab has a unique intelligent monthly incentive system which enables
more than 60% of its sales persons to earn more than 50% of their salaries by way of incentives.

KLab has launched six speciality divisions operating in different therapeutic areas, to enable focus on maximum new product launches.

KLab is a key player in India in the niche areas of oncology, antibiotics, pain and spasm Management.

KLab is a pioneer to bring oncology products in India and has a dedicated formulation and API facility focused on the developing countries. KLab also provides contract manufacturing for more than 10 companies.